This compound is a pharmaceutical intermediate used in the manufacturing of alpha1-adrenergic blockers. It serves as a key intermediate for the production of medications such as alfuzosin, prazosin, terazosin, doxazosin, and IAAP, which are effective as antihypertensives.
Portée du contenu: Les informations de cette page concernent l'identification chimique ainsi que les contextes d'approvisionnement industriel, de recherche et de production. Elles ne constituent ni une allégation thérapeutique, ni un avis médical, ni une notice d'utilisation médicamenteuse.
Approvisionnement ou fourniture de ce composé?
Publiez votre inventaire ou une demande d'achat
CAS 28888-44-0
Lifitegrast Impurity 125
Pharmaceutical impurity reference standard
N-(5-((Diphenylphosphoryl)methyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide
Pharmaceutical intermediate
Tert-Butyl 2-((4R,6S)-6-((E)-2-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)vinyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate
Rosuvastatin calcium intermediate
N-nitroso-tamsulosin
pharmaceutical reference standard
8-bromoquinazoline-2,4(1H,3H)-dione
research compound
6-Bromo-2,4(1H,3H)-quinazolinedione
Pharmaceutical intermediate compound
8-Chloro-6-fluoroquinazoline-2,4-diol
Pharmaceutical intermediate for quinazoline derivatives
7-Bromo-8-fluoro-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione
Pharmaceutical intermediate
6,7-dimethoxy-1H-quinazoline-2,4-dione
KWNQIIMVPSMYEM-UHFFFAOYSA-N
COC1=C(C=C2C(=C1)C(=O)NC(=O)N2)OC